Diffuse large B-cell lymphoma involving the breast. A report of four cases

Francesco Pisani, A. Romano, P. Anticoli Borza, M. Marino, A. Micheli, C. Botti, M. C. Petti

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Non-Hodgkin lymphoma of the breast is an uncommon form of lymphoma occurring either primary disease (PBL) or part of systemic involvement. We report the clinical outcome of 4 consecutive cases with CD20+ diffuse large B-cell lymphoma (DLBCL) of the breast, in the attempt to further clarify the management of this disease. The median age was 53 years (39-61), stages were IIE (n=2), IIIE (n=1), and IV (n=1); IPI scores were 0 (n=2), 2 (n=2). Two cases were PBL, and 2 were secondary involvement of the breast. Two stage HE patients received MACOP-B, radiation therapy was given to one of them and both achieved CR. The stage HIE patient treated with MACOP-B plus Rituximab was in PR at the beginning of the Rituximab and achieved CR at the end of the treatment. The 61-year-old stage IV patient and bilateral involvement received P-VNBEC as first line treatment, achieving PR; she was then treated with 4 cycles of MACOP-B plus Rituximab obtaining CR. After a median follow-up of 40 months (31-50) all patients are alive and in CR. No CNS prophylaxis was given and no incidence of CNS relapse was observed. In our experience DLBCL of the breast shows chemosensitivity to MA-COP-B regimen but the intensification with Rituximab seems to be effective especially in the advanced stages. Further and comparative studies are required to confirm the validity of our results.

Original languageEnglish
Pages (from-to)277-281
Number of pages5
JournalJournal of Experimental and Clinical Cancer Research
Volume25
Issue number2
Publication statusPublished - Jun 2006

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Breast
Disease Management
Reproducibility of Results
Non-Hodgkin's Lymphoma
Lymphoma
Radiotherapy
Recurrence
Rituximab
Incidence
Therapeutics

Keywords

  • Breast lymphoma
  • Lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Diffuse large B-cell lymphoma involving the breast. A report of four cases. / Pisani, Francesco; Romano, A.; Borza, P. Anticoli; Marino, M.; Micheli, A.; Botti, C.; Petti, M. C.

In: Journal of Experimental and Clinical Cancer Research, Vol. 25, No. 2, 06.2006, p. 277-281.

Research output: Contribution to journalArticle

Pisani, Francesco ; Romano, A. ; Borza, P. Anticoli ; Marino, M. ; Micheli, A. ; Botti, C. ; Petti, M. C. / Diffuse large B-cell lymphoma involving the breast. A report of four cases. In: Journal of Experimental and Clinical Cancer Research. 2006 ; Vol. 25, No. 2. pp. 277-281.
@article{1dd9144a3b85415485146aba9a97f961,
title = "Diffuse large B-cell lymphoma involving the breast. A report of four cases",
abstract = "Non-Hodgkin lymphoma of the breast is an uncommon form of lymphoma occurring either primary disease (PBL) or part of systemic involvement. We report the clinical outcome of 4 consecutive cases with CD20+ diffuse large B-cell lymphoma (DLBCL) of the breast, in the attempt to further clarify the management of this disease. The median age was 53 years (39-61), stages were IIE (n=2), IIIE (n=1), and IV (n=1); IPI scores were 0 (n=2), 2 (n=2). Two cases were PBL, and 2 were secondary involvement of the breast. Two stage HE patients received MACOP-B, radiation therapy was given to one of them and both achieved CR. The stage HIE patient treated with MACOP-B plus Rituximab was in PR at the beginning of the Rituximab and achieved CR at the end of the treatment. The 61-year-old stage IV patient and bilateral involvement received P-VNBEC as first line treatment, achieving PR; she was then treated with 4 cycles of MACOP-B plus Rituximab obtaining CR. After a median follow-up of 40 months (31-50) all patients are alive and in CR. No CNS prophylaxis was given and no incidence of CNS relapse was observed. In our experience DLBCL of the breast shows chemosensitivity to MA-COP-B regimen but the intensification with Rituximab seems to be effective especially in the advanced stages. Further and comparative studies are required to confirm the validity of our results.",
keywords = "Breast lymphoma, Lymphoma",
author = "Francesco Pisani and A. Romano and Borza, {P. Anticoli} and M. Marino and A. Micheli and C. Botti and Petti, {M. C.}",
year = "2006",
month = "6",
language = "English",
volume = "25",
pages = "277--281",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "2",

}

TY - JOUR

T1 - Diffuse large B-cell lymphoma involving the breast. A report of four cases

AU - Pisani, Francesco

AU - Romano, A.

AU - Borza, P. Anticoli

AU - Marino, M.

AU - Micheli, A.

AU - Botti, C.

AU - Petti, M. C.

PY - 2006/6

Y1 - 2006/6

N2 - Non-Hodgkin lymphoma of the breast is an uncommon form of lymphoma occurring either primary disease (PBL) or part of systemic involvement. We report the clinical outcome of 4 consecutive cases with CD20+ diffuse large B-cell lymphoma (DLBCL) of the breast, in the attempt to further clarify the management of this disease. The median age was 53 years (39-61), stages were IIE (n=2), IIIE (n=1), and IV (n=1); IPI scores were 0 (n=2), 2 (n=2). Two cases were PBL, and 2 were secondary involvement of the breast. Two stage HE patients received MACOP-B, radiation therapy was given to one of them and both achieved CR. The stage HIE patient treated with MACOP-B plus Rituximab was in PR at the beginning of the Rituximab and achieved CR at the end of the treatment. The 61-year-old stage IV patient and bilateral involvement received P-VNBEC as first line treatment, achieving PR; she was then treated with 4 cycles of MACOP-B plus Rituximab obtaining CR. After a median follow-up of 40 months (31-50) all patients are alive and in CR. No CNS prophylaxis was given and no incidence of CNS relapse was observed. In our experience DLBCL of the breast shows chemosensitivity to MA-COP-B regimen but the intensification with Rituximab seems to be effective especially in the advanced stages. Further and comparative studies are required to confirm the validity of our results.

AB - Non-Hodgkin lymphoma of the breast is an uncommon form of lymphoma occurring either primary disease (PBL) or part of systemic involvement. We report the clinical outcome of 4 consecutive cases with CD20+ diffuse large B-cell lymphoma (DLBCL) of the breast, in the attempt to further clarify the management of this disease. The median age was 53 years (39-61), stages were IIE (n=2), IIIE (n=1), and IV (n=1); IPI scores were 0 (n=2), 2 (n=2). Two cases were PBL, and 2 were secondary involvement of the breast. Two stage HE patients received MACOP-B, radiation therapy was given to one of them and both achieved CR. The stage HIE patient treated with MACOP-B plus Rituximab was in PR at the beginning of the Rituximab and achieved CR at the end of the treatment. The 61-year-old stage IV patient and bilateral involvement received P-VNBEC as first line treatment, achieving PR; she was then treated with 4 cycles of MACOP-B plus Rituximab obtaining CR. After a median follow-up of 40 months (31-50) all patients are alive and in CR. No CNS prophylaxis was given and no incidence of CNS relapse was observed. In our experience DLBCL of the breast shows chemosensitivity to MA-COP-B regimen but the intensification with Rituximab seems to be effective especially in the advanced stages. Further and comparative studies are required to confirm the validity of our results.

KW - Breast lymphoma

KW - Lymphoma

UR - http://www.scopus.com/inward/record.url?scp=33746340263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746340263&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 277

EP - 281

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 2

ER -